Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Relative Selectivity of Covalent Inhibitors Requires Assessment of Inactivation Kinetics and Cellular Occupancy: A Case Study of Ibrutinib and Acalabrutinib.

Hopper M, Gururaja T, Kinoshita T, Dean JP, Hill RJ, Mongan A.

J Pharmacol Exp Ther. 2019 Dec 23. pii: jpet.119.262063. doi: 10.1124/jpet.119.262063. [Epub ahead of print]

2.

Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study.

Burger JA, Barr PM, Robak T, Owen C, Ghia P, Tedeschi A, Bairey O, Hillmen P, Coutre SE, Devereux S, Grosicki S, McCarthy H, Simpson D, Offner F, Moreno C, Dai S, Lal I, Dean JP, Kipps TJ.

Leukemia. 2019 Oct 18. doi: 10.1038/s41375-019-0602-x. [Epub ahead of print]

PMID:
31628428
3.

Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.

Munir T, Brown JR, O'Brien S, Barrientos JC, Barr PM, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Kipps TJ, Moreno C, Montillo M, Burger JA, Byrd JC, Hillmen P, Dai S, Szoke A, Dean JP, Woyach JA.

Am J Hematol. 2019 Dec;94(12):1353-1363. doi: 10.1002/ajh.25638. Epub 2019 Oct 13.

4.

Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.

Coutre SE, Byrd JC, Hillmen P, Barrientos JC, Barr PM, Devereux S, Robak T, Kipps TJ, Schuh A, Moreno C, Furman RR, Burger JA, O'Dwyer M, Ghia P, Valentino R, Chang S, Dean JP, James DF, O'Brien SM.

Blood Adv. 2019 Jun 25;3(12):1799-1807. doi: 10.1182/bloodadvances.2018028761.

5.

Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial.

Mesa RA, Vannucchi AM, Mead A, Egyed M, Szoke A, Suvorov A, Jakucs J, Perkins A, Prasad R, Mayer J, Demeter J, Ganly P, Singer JW, Zhou H, Dean JP, Te Boekhorst PA, Nangalia J, Kiladjian JJ, Harrison CN.

Lancet Haematol. 2017 May;4(5):e225-e236. doi: 10.1016/S2352-3026(17)30027-3. Epub 2017 Mar 20.

PMID:
28336242
6.

Pixantrone-rituximab versus gemcitabine-rituximab in relapsed/refractory aggressive non-Hodgkin lymphoma.

Belada D, Georgiev P, Dakhil S, Inhorn LF, Andorsky D, Beck JT, Quick D, Pettengell R, Daly R, Dean JP, Pavlyuk M, Failloux N, Hübel K.

Future Oncol. 2016 Aug;12(15):1759-68. doi: 10.2217/fon-2016-0137. Epub 2016 Apr 20.

7.

Response of the insulin-like growth factor (IGF) system to IGF-IR inhibition and androgen deprivation in a neoadjuvant prostate cancer trial: effects of obesity and androgen deprivation.

Dean JP, Sprenger CC, Wan J, Haugk K, Ellis WJ, Lin DW, Corman JM, Dalkin BL, Mostaghel E, Nelson PS, Cohen P, Montgomery B, Plymate SR.

J Clin Endocrinol Metab. 2013 May;98(5):E820-8. doi: 10.1210/jc.2012-3856. Epub 2013 Mar 26.

8.

Does chemotherapy have a role before hormone-resistant disease develops?

Dean JP, Higano CS.

Curr Urol Rep. 2009 May;10(3):226-35. Review.

PMID:
19371481
9.

Profiling influences of senescent and aged fibroblasts on prostate carcinogenesis.

Dean JP, Nelson PS.

Br J Cancer. 2008 Jan 29;98(2):245-9. doi: 10.1038/sj.bjc.6604087. Epub 2008 Jan 8. Review.

10.

Evaluation of the Sexual Assessment Monitor, a diagnostic device used to electronically quantify ejaculatory latency time: findings from three studies.

Dinsmore WW, Ralph DJ, Kell P, Wylie KR, Dean JP, Novak C, Wyllie JS, Wyllie MG.

BJU Int. 2006 Sep;98(3):613-8.

11.

The gene expression program of prostate fibroblast senescence modulates neoplastic epithelial cell proliferation through paracrine mechanisms.

Bavik C, Coleman I, Dean JP, Knudsen B, Plymate S, Nelson PS.

Cancer Res. 2006 Jan 15;66(2):794-802.

12.

Redesigning metabolic networks using mathematical programming

Dean JP, Dervakos GA.

Biotechnol Bioeng. 1998 Apr 5;58(2-3):267-71.

PMID:
10191400
13.

In vitro evaluation of a carbon fiber post.

Dean JP, Jeansonne BG, Sarkar N.

J Endod. 1998 Dec;24(12):807-10.

PMID:
10023259
14.
15.

On the topological features of optimal metabolic pathway regimes.

See SM, Dean JP, Dervakos G.

Appl Biochem Biotechnol. 1996 Sep;60(3):251-301.

PMID:
8933718
16.

Use of Nisin in Ice Cream and Effect on the Survival of Listeria monocytogenes .

Dean JP, Zottola EA.

J Food Prot. 1996 May;59(5):476-480. doi: 10.4315/0362-028X-59.5.476.

PMID:
31159057
17.

Three-dimensional flow in the upper ocean.

Weller RA, Dean JP, Price JF, Francis EA, Marra J, Boardman DC.

Science. 1985 Mar 29;227(4694):1552-6.

PMID:
17795332

Supplemental Content

Support Center